BACKGROUND
In extensive-stage small cell lung cancer (ES-SCLC), lurbinectedin is approved for first-line maintenance treatment with atezolizumab and as monotherapy following disease progression, but prospective real-world data on its use are lacking.
METHODS
Jazz EMERGE 402 was a prospective, observational, phase 4 t...
F. Badin, Philip E. Lammers, Geoffrey Liu et al.· Lung Cancer· 0 citations
BACKGROUND
People living with HIV (PWH) are underrepresented in immune checkpoint inhibitor (ICI) and targeted therapy trials, despite a growing burden of malignancies. Cabozantinib may remodel the tumor microenvironment by reducing immunosuppressive myeloid populations and enhancing cytotoxic T-cell infiltration, ther...
Hai-Ying Cheng, Ece Cali, Mumtu Lalla et al.· The Oncologist· 0 citations
Abstract Non–small cell lung cancer (NSCLC) is responsible for the majority of cancer-related mortality worldwide. Lung adenocarcinoma is the most common NSCLC subtype. Despite advances in targeted therapies, treatment resistance remains a critical challenge. Ribonucleotide reductase (RNR), a crucial enzyme in deoxyrib...
Utsav Sen, Dalia Natour, Subhamoy Chakraborty et al.· Cancer Research Communicatio...· 0 citations
A multidisciplinary panel of oncology experts convened to review current evidence gaps, controversies, and unmet needs in the management of lung cancer, highlighting the need for prospective, head‐to‐head clinical trials.
N. Florez, S. Patel, R. Salgia et al.· Cancer· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.